3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
5
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
14
Cisplatin
13
Specimen Handling
11
Magnetic Resonance Spectroscopy
7
Brachytherapy
7
Bevacizumab
7
Radiotherapy
6
atezolizumab
5
Platinum
5
Paclitaxel
5
Nivolumab
5
Human Papillomavirus DNA Tests
5
Gemcitabine
5
Colposcopy
5
Carboplatin
5
Blood Specimen Collection
5
Radiation
4
Fulvestrant
4
lenvatinib
3
Surveys and Questionnaires
3
Radiation Dose Hypofractionation
3
Drug Therapy
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
zimberelimab
2
tisotumab vedotin
2
spartalizumab
2
palbociclib
2
camrelizumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Imlunestrant
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled